FindTrial
Sign In

VE303

DRUG4 trials

Sponsors

Vedanta Biosciences, Inc., Patricia Bloom

Conditions

C. Diff InfectionC.Difficile DiarrheaCDICirrhosisClostridioides DifficileClostridioides Difficile InfectionClostridioides Difficile Infection RecurrenceClostridium Difficile

Phase 1

First-in-human Study of VE303 in Healthy Adult Volunteers
CompletedNCT04236778
Vedanta Biosciences, Inc.Healthy Volunteers
Start: 2017-11-28End: 2019-03-11Updated: 2020-01-27

Phase 2

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
CompletedNCT03788434
Vedanta Biosciences, Inc.CDI, Clostridioides Difficile, Clostridioides Difficile Infection +4
Start: 2019-02-08End: 2021-09-15Updated: 2023-07-03
VE303 for Treatment of Hepatic Encephalopathy (HE)
CompletedNCT04899115
Patricia BloomCirrhosis, Hepatic Encephalopathy
Start: 2021-08-06End: 2023-08-30Updated: 2025-02-07

Phase 3

VE303 for Prevention of Recurrent Clostridioides Difficile Infection
RecruitingNCT06237452
Vedanta Biosciences, Inc.CDI, C.Difficile Diarrhea, C. Diff Infection +7
Start: 2024-05-20End: 2027-10-01Target: 852Updated: 2026-03-31

Related Papers

Safety and efficacy of a defined bacterial consortium, VE303, to treat HE
Hepatology Communications2025-02-191 citations
377. Impact of VE303, a Defined Bacterial Consortium, on Antimicrobial Resistant Gene Prevalence in Patients with <i>Clostridioides difficile</i> Infection (CDI)
Open Forum Infectious Diseases2025-01-29
VE303, a Defined Bacterial Consortium, for Prevention of Recurrent <i>Clostridioides difficile</i> Infection
JAMA2023-04-15160 citations
1953. VE303, a Rationally Designed Bacterial Consortium for Prevention of Recurrent Clostridioides difficile (C. Difficile) infection (rCDI), Stably Restores the Gut Microbiota After Vancomycin (vanco)-Induced Dysbiosis in Adult Healthy Volunteers (HV)
Open Forum Infectious Diseases2019-10-0114 citations